Ainhoa Bilbao Selected Research

Ainhoa Bilbao Research Topics

Disease

8	Alcoholism (Alcohol Abuse) 04/2017 - 01/2005
5	Substance-Related Disorders (Drug Abuse) 01/2021 - 01/2005
4	Pain (Aches) 01/2019 - 01/2005
2	Obesity 08/2023 - 01/2005
2	Schizophrenia (Dementia Praecox) 01/2022 - 03/2007
2	Mental Disorders (Mental Disorder) 01/2021 - 01/2005
2	Parkinson Disease (Parkinson's Disease) 11/2017 - 03/2012
1	Inflammation (Inflammations) 05/2023
1	Acne Vulgaris 05/2023
1	Dystonia (Limb Dystonia) 01/2022
1	Epilepsy (Aura) 01/2022
1	Glaucoma 01/2022
1	Huntington Disease (Huntington's Disease) 01/2022
1	Dementia (Dementias) 01/2022
1	Parkinsonian Disorders (Parkinsonism) 01/2022
1	Chronic Pain 01/2022
1	Nausea 01/2022
1	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 01/2022
1	Irritable Bowel Syndrome (Syndrome, Irritable Bowel) 01/2022
1	Anorexia Nervosa 01/2022
1	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 01/2022
1	Vomiting 01/2022
1	Neuralgia (Stump Neuralgia) 01/2019
1	Neurodegenerative Diseases (Neurodegenerative Disease) 11/2017
1	Cocaine-Related Disorders (Cocaine Addiction) 03/2016
1	Motor Disorders 06/2008
1	Congenital Hypothyroidism (Cretinism) 05/2008
1	Hypothyroidism 05/2008
1	Body Weight (Weight, Body) 12/2007
1	Visceral Pain 12/2007
1	Substance Withdrawal Syndrome (Withdrawal Symptoms) 04/2006
1	Multiple Sclerosis 01/2005
1	Hyperphagia (Overeating) 11/2002

Drug/Important Bio-Agent (IBA)

7	EndocannabinoidsIBA 03/2016 - 01/2005
5	CannabinoidsIBA 01/2021 - 11/2002
3	Dopamine (Intropin)FDA LinkGeneric 09/2017 - 03/2007
3	oleoylethanolamideIBA 01/2016 - 11/2002
2	nabilone (Cesamet)FDA Link 01/2022 - 01/2021
2	Dronabinol (THC)FDA LinkGeneric 01/2022 - 01/2021
2	Ethanol (Ethyl Alcohol)IBA 01/2019 - 07/2007
2	Cannabinoid Receptors (Cannabinoid Receptor)IBA 07/2008 - 01/2005
2	anandamide (arachidonylethanolamide)IBA 07/2008 - 11/2002
1	Antipsychotic Agents (Antipsychotics)IBA 08/2023
1	Virulence Factors (Pathogenicity Factors)IBA 05/2023
1	nabiximols (Sativex)IBA 01/2022
1	CannabidiolIBA 01/2022
1	Therapeutic UsesIBA 01/2022
1	SugarsIBA 01/2021
1	Proteins (Proteins, Gene)FDA Link 11/2017
1	SynucleinsIBA 11/2017
1	Morphine (MS Contin)FDA LinkGeneric 09/2017
1	Dopamine D4 Receptors (Dopamine D4 Receptor)IBA 09/2017
1	L-Type Calcium Channels (Dihydropyridine Receptor)IBA 04/2017
1	Messenger RNA (mRNA)IBA 04/2017
1	mu Opioid Receptors (mu Opioid Receptor)IBA 05/2015
1	Naltrexone (ReVia)FDA LinkGeneric 05/2015
1	NeuropeptidesIBA 01/2013
1	Neurotransmitter Agents (Neurotransmitter)IBA 01/2013
1	MitogensIBA 03/2012
1	Phosphotransferases (Kinase)IBA 03/2012
1	Dopamine D1 Receptors (Dopamine D1 Receptor)IBA 09/2010
1	Glutamic Acid (Glutamate)FDA Link 09/2010
1	Cocaine (Cocaine HCl)IBA 09/2010
1	N-Methylaspartate (NMDA)IBA 08/2009
1	Protein Synthesis InhibitorsIBA 08/2009
1	CB1 Cannabinoid Receptor (CB1 Receptor)IBA 07/2008
1	cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester (URB597)IBA 07/2008
1	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 12/2007
1	Analgesics (Analgesic Drugs)IBA 12/2007
1	PPAR alphaIBA 12/2007
1	TRPV Cation ChannelsIBA 12/2007
1	Caffeine (No Doz)FDA LinkGeneric 04/2006
1	Naloxone (Narcan)FDA LinkGeneric 04/2006

Therapy/Procedure

1	Denervation 01/2019
1	Precision Medicine 05/2015
1	Therapeutics 09/2010